HC Wainwright Analysts Lower Earnings Estimates for RNAC

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Cartesian Therapeutics to a loss of $0.99 per share from $0.94, while maintaining a “Buy” rating and $25 price target.
• Cartesian reported quarterly EPS of $0.46, beating consensus expectations for a $0.88 loss by $1.34.
• RNAC shares opened at $8.76, with the stock valued at approximately $265 million; institutional investors own 86.95% of outstanding shares, and analysts’ consensus rating is “Moderate Buy” with a $32.60 target price.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - HC Wainwright reduced their Q3 2026 earnings estimates for shares of Cartesian Therapeutics in a research report issued to clients and investors on Friday, August 7th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.99) per share for the quarter, down from their prior estimate of ($0.94). HC Wainwright has a "Buy" rating and a $25.00 price objective on the stock. The consensus estimate for Cartesian Therapeutics' current full-year earnings is ($3.99) per share. HC Wainwright also issued estimates for Cartesian Therapeutics' Q4 2026 earnings at ($1.06) EPS, FY2026 earnings at ($2.91) EPS, Q1 2027 earnings at ($1.09) EPS, Q2 2027 earnings at ($0.95) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.83) EPS and FY2027 earnings at ($3.62) EPS.

Other research analysts also recently issued reports about the company. Weiss Ratings raised Cartesian Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, June 12th. Needham & Company LLC reiterated a "buy" rating and issued a $40.00 target price on shares of Cartesian Therapeutics in a report on Tuesday, June 9th. Zacks Research upgraded Cartesian Therapeutics from a "strong sell" rating to a "hold" rating in a report on Wednesday, July 29th. BTIG Research reaffirmed a "buy" rating and set a $44.00 price objective on shares of Cartesian Therapeutics in a research report on Tuesday, June 9th. Finally, Wedbush reiterated an "outperform" rating and set a $38.00 target price on shares of Cartesian Therapeutics in a research report on Wednesday, June 10th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $32.60.

Cartesian Therapeutics Trading Down 1.0%

Shares of RNAC opened at $8.76 on Tuesday. The stock has a market capitalization of $264.99 million, a P/E ratio of -1.47 and a beta of 0.63. The firm's fifty day simple moving average is $8.61 and its two-hundred day simple moving average is $7.56. Cartesian Therapeutics has a 12 month low of $5.60 and a 12 month high of $12.25.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.46 earnings per share for the quarter, topping the consensus estimate of ($0.88) by $1.34.

Institutional Investors Weigh In On Cartesian Therapeutics

A number of hedge funds have recently made changes to their positions in the business. R Squared Ltd bought a new position in Cartesian Therapeutics during the fourth quarter worth about $74,000. Sei Investments Co. bought a new stake in shares of Cartesian Therapeutics during the first quarter valued at about $78,000. Wells Fargo & Company MN increased its position in shares of Cartesian Therapeutics by 49.2% during the fourth quarter. Wells Fargo & Company MN now owns 11,762 shares of the company's stock valued at $85,000 after buying an additional 3,878 shares during the period. Miller Financial Services LLC lifted its holdings in shares of Cartesian Therapeutics by 17.2% in the fourth quarter. Miller Financial Services LLC now owns 13,643 shares of the company's stock worth $98,000 after buying an additional 2,000 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Cartesian Therapeutics in the fourth quarter valued at approximately $112,000. 86.95% of the stock is currently owned by institutional investors.

About Cartesian Therapeutics

Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian's technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian's approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source